Biologics for severe asthma and beyond

Akinlade, 2019, Conjunctivitis in dupilumab clinical trials, The British Journal of Dermatology, 181, 459, 10.1111/bjd.17869 Albers, 2018, Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study, The Journal of Asthma, 55, 152, 10.1080/02770903.2017.1322611 Alhossan, 2017, “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: Meta-analysis, The Journal of Allergy and Clinical Immunology. In Practice, 5, 1362, 10.1016/j.jaip.2017.02.002 Ali, 2021, Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis, Oxford Medical Case Reports, 2021, 10.1093/omcr/omaa029 Aydın, 2015, Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center’s experience with 14 cases, Allergy and Asthma Proceedings, 36, 493, 10.2500/aap.2015.36.3909 Bachert, 2019, Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials, The Lancet, 394, 1638, 10.1016/S0140-6736(19)31881-1 Bachert, 2022, Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial, The Journal of Allergy and Clinical Immunology, 149, 1309, 10.1016/j.jaci.2021.08.030 Bel, 2014, Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma, The New England Journal of Medicine, 371, 1189, 10.1056/NEJMoa1403291 Benes, 2021, Successful treatment of refractory status asthmaticus with omalizumab: A case report, Allergy, Asthma and Clinical Immunology, 17, 128, 10.1186/s13223-021-00629-z Biener, 2023, Impact of short-term pausing of oral corticosteroids on blood eosinophil count in patients with severe asthma, Pneumologie, 77, 357, 10.1055/a-1956-8800 Bjermer, 2016, Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study, Chest, 150, 789, 10.1016/j.chest.2016.03.032 Bleecker, 2016, Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, The Lancet, 388, 2115, 10.1016/S0140-6736(16)31324-1 Bleecker, 2018, Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma, The European Respiratory Journal, 52, 10.1183/13993003.00936-2018 Bousquet, 2007, Predicting and evaluating response to omalizumab in patients with severe allergic asthma, Respiratory Medicine, 101, 1483, 10.1016/j.rmed.2007.01.011 Briegel, 2021, Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP, The Journal of Allergy and Clinical Immunology. In Practice, 9, 4477, 10.1016/j.jaip.2021.07.049 Brightling, 2021, Risankizumab in severe asthma - A phase 2a, placebo-controlled trial, The New England Journal of Medicine, 385, 1669, 10.1056/NEJMoa2030880 Brusselle, 2017, Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils, Pulmonary Pharmacology & Therapeutics, 43, 39, 10.1016/j.pupt.2017.01.011 Brusselle, 2022, Biologic therapies for severe asthma, The New England Journal of Medicine, 386, 157, 10.1056/NEJMra2032506 Buhl, 2022, Effective management of severe asthma with biologic medications in adult patients: A literature review and international expert opinion, The Journal of Allergy and Clinical Immunology. In Practice, 10, 422, 10.1016/j.jaip.2021.10.059 Busse, 2001, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, The Journal of Allergy and Clinical Immunology, 108, 184, 10.1067/mai.2001.117880 Busse, 2013, High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects, Journal of Allergy and Clinical Immunology, 132, 485, 10.1016/j.jaci.2013.02.032 Busse, 2019, Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial, The Lancet Respiratory Medicine, 7, 46, 10.1016/S2213-2600(18)30406-5 Busse, 2021, Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma, European Respiratory Journal, 58, 2004605, 10.1183/13993003.04605-2020 Campisi, 2021, Real-world experience with dupilumab in severe asthma: One-year data from an Italian named patient program, Journal of Asthma Allergy, 14, 575, 10.2147/JAA.S312123 Carpagnano, 2020, Switching from omalizumab to mepolizumab: real-life experience from Southern Italy, Therapeutic Advances in Respiratory Disease, 14, 10.1177/1753466620929231 Carpagnano, 2022, Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management, Multidisciplinary Respiratory Medicine, 17, 797 Carpagnano, 2023 Caruso, 2022, Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis, Frontiers in Medicine (Lausanne), 9 Casale, 2018, Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma, Allergy, 73, 490, 10.1111/all.13302 Casale, 2019, Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study, The Journal of Allergy and Clinical Immunology. In Practice, 7, 156, 10.1016/j.jaip.2018.04.043 Castro, 2018, Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma, The New England Journal of Medicine, 378, 2486, 10.1056/NEJMoa1804092 Castro, 2015, Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials, The Lancet Respiratory Medicine, 3, 355, 10.1016/S2213-2600(15)00042-9 Celebi Sozener, 2018, Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): Single-center experience in 18 cases, World Allergy Organization Journal, 11, 39, 10.1186/s40413-018-0217-0 Chapman, 2019, The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma, Allergy, 74, 1716, 10.1111/all.13850 Chipps, 2018, Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma, Annals of Allergy, Asthma & Immunology, 120, 504, 10.1016/j.anai.2018.01.030 Chung, 2014, International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma, The European Respiratory Journal, 43, 343, 10.1183/09031936.00202013 Chupp, 2017, Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial, The Lancet Respiratory Medicine, 5, 390, 10.1016/S2213-2600(17)30125-X Corren, 2016, Phase 3 study of reslizumab in patients with poorly controlled asthma: Effects across a broad range of eosinophil counts, Chest, 150, 799, 10.1016/j.chest.2016.03.018 Dellon, 2022, Dupilumab in adults and adolescents with eosinophilic esophagitis, New England Journal of Medicine, 387, 2317, 10.1056/NEJMoa2205982 Detoraki, 2016, Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: A 36-month follow-up study, The Journal of Asthma, 53, 201, 10.3109/02770903.2015.1081700 Domingo, 2023 Drick, 2020, Switch from IL-5 to IL-5-receptor α antibody treatment in severe eosinophilic asthma, Journal of Asthma Allergy, 13, 605, 10.2147/JAA.S270298 Drick, 2018, Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response, BMC Pulmonary Medicine, 18, 119, 10.1186/s12890-018-0689-2 Drick, 2022, Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD, ERJ Open Research, 8, 207, 10.1183/23120541.00207-2022 Dupin, 2020, Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort, Clinical and Experimental Allergy, 50, 789, 10.1111/cea.13614 Eger, 2021, Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma, The Journal of Allergy and Clinical Immunology. In Practice, 9, 2913, 10.1016/j.jaip.2021.02.042 Fahy, 2015, Type 2 inflammation in asthma--present in most, absent in many, Nature Reviews. Immunology, 15, 57, 10.1038/nri3786 FDA FitzGerald, 2018, Predictors of enhanced response with benralizumab for patients with severe asthma: Pooled analysis of the SIROCCO and CALIMA studies, The Lancet Respiratory Medicine, 6, 51, 10.1016/S2213-2600(17)30344-2 FitzGerald, 2016, Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet, 388, 2128, 10.1016/S0140-6736(16)31322-8 Frohlich, 2022, Eosinophilic pulmonary complications of dupilumab in 2 patients with asthma and chronic rhinosinusitis with nasal polyps, The Journal of Allergy and Clinical Immunology: In Practice, 10, 617 García-Marcos, 2023, Asthma management and control in children, adolescents, and adults in 25 countries: A Global Asthma Network Phase I cross-sectional study, The Lancet Global Health, 11, e218, 10.1016/S2214-109X(22)00506-X Gevaert, 2020, Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials, The Journal of Allergy and Clinical Immunology, 146, 595, 10.1016/j.jaci.2020.05.032 GINA Guntur, 2021, Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis, The Journal of Allergy and Clinical Immunology. In Practice, 9, 1186, 10.1016/j.jaip.2020.09.054 Han, 2021, Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet Respiratory Medicine, 9, 1141, 10.1016/S2213-2600(21)00097-7 Hanania, 2011, Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial, Annals of Internal Medicine, 154, 573, 10.7326/0003-4819-154-9-201105030-00002 Hanania, 2013, Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study, American Journal of Respiratory and Critical Care Medicine, 187, 804, 10.1164/rccm.201208-1414OC Harrison, 2020, Real-world mepolizumab in the prospective severe asthma REALITI-A study: Initial analysis, The European Respiratory Journal, 56, 10.1183/13993003.00151-2020 Harrison, 2021, Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): A randomised, controlled, phase 3b trial, The Lancet Respiratory Medicine, 9, 260, 10.1016/S2213-2600(20)30414-8 Harvey, 2020, Mepolizumab effectiveness and identification of super-responders in severe asthma, The European Respiratory Journal, 55, 10.1183/13993003.02420-2019 Hashimoto, 2022, Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – “first initiators” and “switchers”, European Respiratory Journal, 60, 2164 Hashimoto, 2022, Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - First initiators and switchers, The Journal of Allergy and Clinical Immunology. In Practice, 10, 2099, 10.1016/j.jaip.2022.04.014 Hearn, 2021, The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma, The Journal of Allergy and Clinical Immunology. In Practice, 9, 2093, 10.1016/j.jaip.2021.01.008 Holguin, 2020, Management of severe asthma: A European Respiratory Society/American Thoracic Society guideline, The European Respiratory Journal, 55, 10.1183/13993003.00588-2019 Humbert, 2005, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE, Allergy, 60, 309, 10.1111/j.1398-9995.2004.00772.x Humbert, 2018, Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: The STELLAIR study, The European Respiratory Journal, 51, 10.1183/13993003.02523-2017 Jachiet, 2016, Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Data on seventeen patients, Arthritis & Rhematology, 68, 2274, 10.1002/art.39663 Kavanagh, 2020, Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma, Chest, 158, 491, 10.1016/j.chest.2020.03.042 Kavanagh, 2021, Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma, Allergy, 76, 1890, 10.1111/all.14693 Kavanagh, 2021, Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma, Allergy, 76, 1890, 10.1111/all.14693 Kavanagh, 2021, Real-world effectiveness of benralizumab in severe eosinophilic asthma, Chest, 159, 496, 10.1016/j.chest.2020.08.2083 Kayser, 2021, Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months, Journal of Asthma Allergy, 14, 863, 10.2147/JAA.S319572 Kelsen, 2021, Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial, The Journal of Allergy and Clinical Immunology, 148, 790, 10.1016/j.jaci.2021.03.044 Kim, 2020, Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report, SAGE Open Medical Case Reports, 8, 10.1177/2050313X20940458 Kim, 2010, Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome, The Journal of Allergy and Clinical Immunology, 125, 1336, 10.1016/j.jaci.2010.03.028 Kolbeck, 2010, MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function, The Journal of Allergy and Clinical Immunology, 125, 1344, 10.1016/j.jaci.2010.04.004 Kuang, 2019, Benralizumab for PDGFRA-negative hypereosinophilic syndrome, The New England Journal of Medicine, 380, 1336, 10.1056/NEJMoa1812185 Le Floc’h, 2020, Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation, Allergy, 75, 1188, 10.1111/all.14151 Lommatzsch, 2022, Disease-modifying anti-asthmatic drugs, The Lancet, 399, 1664, 10.1016/S0140-6736(22)00331-2 Lommatzsch, 2023, A2BCD: A concise guide for asthma management, The Lancet Respiratory Medicine, 11, 573, 10.1016/S2213-2600(22)00490-8 Lommatzsch Lommatzsch, 2021, Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia, Allergy, 76, 2920, 10.1111/all.14964 Lommatzsch, 2022, Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations, Allergy, 77, 2839, 10.1111/all.15379 Magnan, 2016, Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, 71, 1335, 10.1111/all.12914 Martínez-Moragón, 2021, Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study), BMC Pulmonary Medicine, 21, 417, 10.1186/s12890-021-01785-z Martínez-Rivera, 2021, Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis, BMC Pulmonary Medicine, 21, 35, 10.1186/s12890-021-01397-7 Maurer, 2013, Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria, The New England Journal of Medicine, 368, 924, 10.1056/NEJMoa1215372 Menzella, 2019, A case of chronic eosinophilic pneumonia in a patient treated with dupilumab, Therapeutics and Clinical Risk Management, 15, 869, 10.2147/TCRM.S207402 Menzella, 2020, Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma, Pulmonary Pharmacology & Therapeutics, 64, 10.1016/j.pupt.2020.101966 Menzies-Gow, 2020, An expert consensus framework for asthma remission as a treatment goal, The Journal of Allergy and Clinical Immunology, 145, 757, 10.1016/j.jaci.2019.12.006 Menzies-Gow, 2021, Tezepelumab in adults and adolescents with severe, uncontrolled asthma, The New England Journal of Medicine, 384, 1800, 10.1056/NEJMoa2034975 Menzies-Gow, 2022, Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): A multicentre, open-label, single-arm study, The Lancet Respiratory Medicine, 10, 47, 10.1016/S2213-2600(21)00352-0 Menzies-Gow, 2023, Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): A randomised, placebo-controlled extension study, The Lancet Respiratory Medicine, 11, 425, 10.1016/S2213-2600(22)00492-1 Menzies-Gow, 2022, Real world biologic use and switch patterns in severe asthma: Data from the international severe asthma registry and the US CHRONICLE study, Journal of Asthma Allergy, 15, 63, 10.2147/JAA.S328653 Milger, 2023, Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS), Pneumologie, 77, 220, 10.1055/a-2014-4350 Milger, 2023, Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS), Pneumologie, 77, 220, 10.1055/a-2014-4350 Milger, 2019, Omalizumab rescue therapy for refractory status asthmaticus, Annals of Internal Medicine, 170, 351, 10.7326/L18-0359 Milger, 2023, Response to biologics and clinical remission in the adult German asthma net severe asthma registry cohort, The Journal of Allergy and Clinical Immunology. In Practice, 11, 2701, 10.1016/j.jaip.2023.05.047 Morobeid, 2021, Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma, ERJ Open Research, 7, 190, 10.1183/23120541.00190-2021 Mosmann, 1986, Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, Journal of Immunology, 136, 2348, 10.4049/jimmunol.136.7.2348 Mukherjee, 2018, Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab, American Journal of Respiratory and Critical Care Medicine, 197, 38, 10.1164/rccm.201707-1323OC Mümmler, 2020, Differential response to biologics in a patient with severe asthma and ABPA: A role for dupilumab?, Allergy, Asthma and Clinical Immunology, 16, 55, 10.1186/s13223-020-00454-w Mümmler, 2021, Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy, The Journal of Allergy and Clinical Immunology. In Practice, 9, 1177, 10.1016/j.jaip.2020.09.014 Mümmler, 2022, Overall response to Anti-IL-5/Anti-IL5-Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness, The Journal of Allergy and Clinical Immunology. In Practice, 10, 3174, 10.1016/j.jaip.2022.07.007 Nair, 2017, Oral glucocorticoid-sparing effect of benralizumab in severe asthma, The New England Journal of Medicine, 376, 2448, 10.1056/NEJMoa1703501 Namazy, 2015, The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy, The Journal of Allergy and Clinical Immunology, 135, 407, 10.1016/j.jaci.2014.08.025 Nanzer, 2020, Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis, ERJ Open Research, 6, 10.1183/23120541.00451-2020 Nowsheen, 2021, Real-world efficacy and safety of dupilumab use in the treatment of asthma, Annals of Allergy, Asthma & Immunology, 127, 147, 10.1016/j.anai.2021.04.011 Numata, 2022, Real-world effectiveness of dupilumab for patients with severe asthma: A retrospective study, Journal of Asthma Allergy, 15, 395, 10.2147/JAA.S357548 Ortega, 2019, Combination biologic therapy for severe persistent asthma, Annals of Allergy, Asthma & Immunology, 123, 309, 10.1016/j.anai.2019.06.013 Ortega, 2014, Mepolizumab treatment in patients with severe eosinophilic asthma, The New England Journal of Medicine, 371, 1198, 10.1056/NEJMoa1403290 Ortega, 2016, Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: A secondary analysis of the DREAM and MENSA studies, The Lancet Respiratory Medicine, 4, 549, 10.1016/S2213-2600(16)30031-5 Ortega, 2014, The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia, European Respiratory Journal, 44, 239, 10.1183/09031936.00220413 Padilla-Galo, 2020, Real-life experience with benralizumab during 6 months, BMC Pulmonary Medicine, 20, 184, 10.1186/s12890-020-01220-9 Padoan, 2020, Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis, The Journal of Allergy and Clinical Immunology. In Practice, 8, 3225, 10.1016/j.jaip.2020.05.033 Pavord, 2023 Pavord, 2012, Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet, 380, 651, 10.1016/S0140-6736(12)60988-X Pelaia, 2019, Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose, Pulmonary Pharmacology & Therapeutics, 58, 10.1016/j.pupt.2019.101830 Pelaia, 2023 Pérez de Llano, 2019, Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: A multicenter, open-label pilot study, The Journal of Allergy and Clinical Immunology: In Practice, 7, 2277 Pérez de Llano, 2022, Asthma control in patients with severe eosinophilic asthma treated with reslizumab: Spanish real-life data, Journal of Asthma Allergy, 15, 79, 10.2147/JAA.S340562 Pérez de Llano, 2020, Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab, Allergy, 75, 940, 10.1111/all.14035 Pérez-de-Llano, 2011, Effects of omalizumab in Aspergillus-associated airway disease, Thorax, 66, 539, 10.1136/thx.2010.153312 Peters, 2014, Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma, The Journal of Allergy and Clinical Immunology, 133, 388, 10.1016/j.jaci.2013.07.036 Pilette, 2022, REALITI-A study: Real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma, The Journal of Allergy and Clinical Immunology. In Practice, 10, 2646, 10.1016/j.jaip.2022.05.042 Press Release Presta, 1993, Humanization of an antibody directed against IgE, The Journal of Immunology, 151, 2623, 10.4049/jimmunol.151.5.2623 Rabe, 2018, Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma, The New England Journal of Medicine, 378, 2475, 10.1056/NEJMoa1804093 Ramonell, 2020, Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series, The Journal of Allergy and Clinical Immunology. In Practice, 8, 742, 10.1016/j.jaip.2019.11.031 Roan, 2019, Epithelial cell–derived cytokines: more than just signaling the alarm, The Journal of Clinical Investigation, 129, 1441, 10.1172/JCI124606 Robinson, 2023 Rothenberg, 2023 Roufosse, 2020, Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial, The Journal of Allergy and Clinical Immunology, 146, 1397, 10.1016/j.jaci.2020.08.037 Schleich, 2014, Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR), Respiratory Medicine, 108, 1723, 10.1016/j.rmed.2014.10.007 Schleich, 2020, Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature, The Journal of Allergy and Clinical Immunology. In Practice, 8, 2412, 10.1016/j.jaip.2020.03.023 Senner, 2020, Psoriasis bei Dupilumab-behandeltem atopischem Ekzem, Der Hautarzt, 71, 383, 10.1007/s00105-020-04565-8 Simpson, 2016, Two phase 3 trials of dupilumab versus placebo in atopic dermatitis, The New England Journal of Medicine, 375, 2335, 10.1056/NEJMoa1610020 Soeda, 2019, Allergic bronchopulmonary aspergillosis successfully treated with benralizumab, The Journal of Allergy and Clinical Immunology. In Practice, 7, 1633, 10.1016/j.jaip.2018.11.024 Soeda, 2019, Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab, Allergology International, 68, 377, 10.1016/j.alit.2018.12.008 Soler, 2001, The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics, European Respiratory Journal, 18, 254, 10.1183/09031936.01.00092101 Sposato, 2019, Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes, The Journal of Allergy and Clinical Immunology. In Practice, 7, 1643, 10.1016/j.jaip.2019.03.006 Takenaka, 2019, Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis, Allergology International, 68, 539, 10.1016/j.alit.2019.04.006 Terashima, 2018, A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab, BMC Pulmonary Medicine, 18, 53, 10.1186/s12890-018-0617-5 Thomas, 2023, Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients, Allergy, 10.1111/all.15867 Tillie-Leblond, 2011, Allergic bronchopulmonary aspergillosis and omalizumab, Allergy, 66, 1254, 10.1111/j.1398-9995.2011.02599.x To, 2012, Global asthma prevalence in adults: Findings from the cross-sectional world health survey, BMC Public Health, 12, 204, 10.1186/1471-2458-12-204 Tomomatsu, 2023, Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis, Scientific Reports, 13, 5468, 10.1038/s41598-023-32246-8 van Toor, 2021, Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: Response rate, effectiveness, and safety, The Journal of Asthma, 58, 651, 10.1080/02770903.2020.1723623 Tsubouchi, 2023 van der Veer, 2021, Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab, Clinical and Translational Allergy, 11, 10.1002/clt2.12081 Voskamp, 2015, Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis, The Journal of Allergy and Clinical Immunology. In Practice, 3, 192, 10.1016/j.jaip.2014.12.008 Wechsler, 2017, Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis, The New England Journal of Medicine, 376, 1921, 10.1056/NEJMoa1702079 Wechsler, 2022, Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): A randomised, placebo-controlled, phase 3 study, The Lancet Respiratory Medicine, 10, 650, 10.1016/S2213-2600(21)00537-3 Wechsler, 2021, Efficacy and safety of itepekimab in patients with moderate-to-severe asthma, The New England Journal of Medicine, 385, 1656, 10.1056/NEJMoa2024257 Wechsler, 2009, Churg-strauss syndrome in patients treated with omalizumab, Chest, 136, 507, 10.1378/chest.08-2990